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the Graft-Versus-Host Disease Prophylaxis Regimen
Kinya Ohata, J. Luis Espinoza, Xuzhang Lu, Yukio Kondo, Shinji NakaoTo determine how immunosuppressant agents used for graft-versus-host disease (GVHD) prophylaxis affect
natural killer (NK) cells, we examined the effects of cyclosporine (CSP), tacrolimus (TAC), mycophenolic acid
(MPA, an active form of mycophenolate mofetil), and methotrexate (MTX) on the proliferation and cytotox-
icity of NK cells. The proliferation of NK cells from healthy individuals in the presence of interleukin (IL)-2
and IL-15 was suppressed to 51%6 16% of that of the controls with CSP, to 31%6 19% with TAC, to 14%6
6% with MPA, and to 87% 6 18% with MTX. Both CSP and TAC increased the proportion of
CD16-CD56bright cells, a NK cell subset capable of secreting high amount of cytokines, and also enhanced
NKp30 expression, whereas MPAmarkedly decreased the proportion of CD16-CD56bright cells and reduced
the expression of all activating NK cell receptors, including NKG2D, NKp30, NKp44, and NKp46. MPA also
reduced the cytotoxicity against K562 cells from 61%6 15% to 17%6 7% and that against Daudi cells from
44%6 4% to 4%6 4%, whereas the other 3 drugs did not diminish these cytotoxicities. The inhibition of NK
cell proliferation and cytotoxicity against leukemic cell lines by MPAwas partially abolished by the inclusion of
guanosine in the culture. Similar to the effect of MPA on T cells, MPA inhibited the down-regulation of p27 on
NK cells induced by the incubation of NK cells in the presence of IL-2. These results suggest that MPA is
a potent inhibitor of NK cells, and that its inclusion in the GVHD prophylaxis regimen might diminish the
graft-versus-leukemia effect of NK cells.
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Graft-versus-host disease (GVHD) and disease
relapse aremajor causes ofmorbidity andmortality after
allogeneic hematopoietic stemcell transplantation (allo-
HSCT) for hematologic disease. Both murine and hu-
man studies show that natural killer (NK) cells mediate
a number of potentially beneficial effects after allo-
HSCT, including the elimination of residual malignant
cells and virally infected cells [1,2]. The Perugia group
demonstrated that NK cells play a critical role in theCellular Transplantation Biology, Kanazawa University
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fect [2,3]. Patients with acute myelogenous leukemia
(AML) who received a haploidentical transplant from
a killer immune globulin–like receptor (KIR) ligand–
mismatched donor in the GVHD direction showed
a marked reduction in the relapse rate compared with
an otherwise similar group of AML patients without
this mismatch (3% vs 47%) [4].
In contrast to several subsequent reports support-
ing that original report, a large retrospective study of
T cell–replete transplantation from the National Mar-
rowDonor Program showed no decrease in the relapse
rate of AML following KIR-mismatched transplanta-
tion [5]. Similarly negative results have been reported
by other groups as well [6,7]. Those studies differed
in various respects, including donor source (related
vs unrelated), HLA parity of donors (haploidentical
vs matched unrelated), T cell content in the graft
(strictly depleted vs T cell replete), and the use of
posttransplantation immunosuppression (absent vs
present). The GVHD prophylaxis regimen may
particularly affect the potency of the GVL effect by205
206 Biol Blood Marrow Transplant 17:205-213, 2011K. Ohata et al.NK cells. Wang et al. [8] recently reported that cyclo-
sporine (CSP) augments NK cell cytotoxicity against
leukemia cell lines.
In addition to CSP and methotrexate (MTX), new
immunosuppressants, including tacrolimus (TAC) and
the inosine monophosphate dehydrogenase (IMPDH)
inhibitor mycophenolate mofetil (MMF), are being
successfully used for GVHD prophylaxis. Although
sparing NK cells from the inhibitory effect of immu-
nosuppressants is potentially important to retain the
GVL effect after allo-HSCT, precisely how these new
drugs influence NK cells remains to be clarified. In the
present study, we compared the effects of 4 different
immunosuppressants on NK cells and found a potent
inhibitory effect of mycophenolic acid (MPA), an
active form of MMF, on NK cells.MATERIALS AND METHODS
CD32CD561NK Cell Enrichment
Peripheral bloodmononuclear cells (PBMCs) were
isolated from 7 healthy donors using lymphocyte sepa-
ration media. After washing with phosphate-buffered
saline, PBMCs were subjected to NK cell enrichment
using the negative selection with immunomagnetic
beads (Dynal NK cell isolation kit; Invitrogen Dynal
AS, Smestad,Norway) according to themanufacturer’s
recommendations. Enriched NK cells contained more
than 85%-90% CD561CD3- (data not shown).
NK Cell Culture
Enriched NK cell populations were cultured in
Dulbecco’s Modified Eagle’s Medium/Hams F12
(2:1) with 10% human AB- sera, 2-b mercaptoethanol
(24 mM), L-ascorbic acid (24 mg/L), sodium selenite
(50 mg/L), ethanolamine (50 mM), and penicillin-
streptomycin (100 U/mL of each). At the start of
each culture, interleukin (IL)-2 (100 U/mL) and IL-
15 (10 ng/mL) were added to the culture medium
[8]. Then 4 different immunosuppressive drugs were
added to the culture at the following concentrations:
CSP, 1000 ng/mL; TAC, 20 ng/mL; MPA, 10 mg/mL;
and MTX, 100 ng/mL. Each drug was diluted with
ethanol and included in the culture at the indicated
concentration. Vehicle control cultures were set up
in parallel using ethanol (EtOH) at a final concentra-
tion of 0.1%. In some experiments, guanosine was
included in the culture at a concentration of 100 mM
with MPA.
Reagents and Cell Lines
The immunosuppressants were kindly provided by
the producers: CSP, Novartis Pharma, Tokyo, Japan;
TAC, Astellas Pharma, Tokyo, Japan; MTX, Wyeth,
Tokyo, Japan; and MPA, Roche Bioscience, Tokyo,Japan. Guanosine was purchased from Sigma-Aldrich
(St Louis, MO). K562 and Daudi were purchased
from the Health Science Research Resources Bank
(Osaka, Japan) and RIKEN BRC (Ibaraki, Japan),
respectively.
Phenotypic Analysis of NK Cells
TheNK cell surface phenotype was determined by
3-color flow cytometry. Fresh or cultured NK cells
were stained with various monoclonal antibodies spe-
cific to cell surface proteins, including CD3, CD56,
and CD16 (BD Pharmingen, Franklin Lakes, NJ)
andNKG2D,NKp30, NKp44, andNKp46 (Beckman
Coulter, Marseille, France), and then analyzed with
a FACScan flow cytometer (BD Bioscience, Mountain
View, CA).
Carboxy Fluoroscein Succinimidyl Ester
Staining
NK cells were stained with carboxy fluoroscein
succinimidyl ester (CFSE) using the Cell Trace
CFSE Cell Proliferation Kit (Invitrogen, Carlsbad,
CA). After a 10-minute incubation with CFSE, NK
cells were cultured in the presence or absence of each
drug. TheCFSE content of theNK cells wasmeasured
using the FACScan flow cytometer at various time
points during the culture.
Cytotoxicity Assay of NKCells against Leukemia
Cell Lines
NK cell cytotoxicity against K562 and Daudi cells
was assessed using a standard chromium-release assay
[9]. The percentage of specific lysis was calculated using
the following formula: 100  (count per minute [cpm]
released from test sample – cpm spontaneous release)/
(cpm maximum release2 cpm spontaneous release).
Western Blot Analysis
The preparations of activated T cells, as well as
their MPA and IL-2 treatments, were as described by
Quemeneur et al. [10]. Freshly isolated NK cells and
activated T cells were cultured for the indicated times
in the presence or absence of IL-2 with and without
MPA. Lysates of NK cells and T cells were subjected
to Western blot analysis as described previously [11],
with minor modifications. In brief, the cultured cells
were sonicated using a Sonifier B-12 cell disrupter
(Branson, Danbury, CT). Equal amounts of the lysate
proteins were separated by 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and then
transferred onto polyvinylidene difluoride membranes
(Millipore, Schwalbach, Germany). The membranes
were incubated with the primary antibodies (rabbit
anti-human p27 pAb; Ana Spec, San Jose, CA) and
mouse anti-human a-tubulin antibody (Sigma-Aldrich),
and then incubated with the appropriate horseradish
Biol Blood Marrow Transplant 17:205-213, 2011 207MPA Inhibits NK Cell Proliferation and Cytotoxicityperoxide–labeled secondary antibody. Specific bands
were visualized using a peroxidase chemiluminescent
substrate (Pierce, Rockford, IL) and analyzed using
an LAS-4000 luminescent image analyzer (Fujifilm,
Tokyo, Japan).
Statistical Analyses
The significance of differences in cell number, per-
centage of CD161CD56- cells, and cytotoxicity
among NK cells cultured in the presence of different
immunosuppressants was assessed by the Student
t test. The significance of differences in the expression
levels of NKG2D, NKp30, NKp44, and NKp46
among NK cells cultured with different immunousup-
pressants was assessed by the Mann-Whitney U test.
A P value\.05 was considered significant.RESULTS
Effects of Immunosuppressants on NK Cell
Proliferation
NK cells isolated from 7 healthy donors were cul-
tured in the presence of interleukin (IL)-2 (100 U/mL)
and IL-15 (10 ng/mL) with CSP 1000 ng/mL [12],
TAC 20 ng/mL [13], MTX 100 ng/mL [14], MPAFigure 1. Effect of immunosuppressants on the proliferation of NK cells induc
cultured in the presence of IL-2 (100 U/mL) and IL-15 (10 ng/mL) with a vehicle
MTX 100 ng/mL) for 7 days. The vertical axis represents the fold expansion (m
after culture by that before culture. An asterisk indicates values showing signifi
CFSE contents in CD3-CD561 cells were determined using flow cytometry
histograms from a healthy individual. The results from 5 other individuals sho
(100 U/mL) and IL-15 (10 ng/mL) with MPA (1-100 mg/mL) for 7 days. The ver
calculated by dividing the number of cells after culture by that before culture. A
compared with the vehicle controls.10 mg/mL [15], or vehicle control (EtOH 0.1%), and
the number of NK cells in each culture was measured
after 7 days (Figure 1A). The concentration of each im-
munosuppressant in the culture medium was similar to
the peak level measured in the blood after the admin-
istration of standard doses. CSP, TAC, and MPA sig-
nificantly inhibited the proliferation of NK cells, with
MPA having the strongest inhibitory effect, whereas
MTX did not influence NK cell proliferation.
Next, freshly isolated NK cells were labeled with
the membrane dye CFSE and cultured under the
same conditions as described above. The CFSE levels
inNK cells harvested at days 1, 5, and 9 of culture were
determined by flow cytometry. Although all 4 immu-
nosuppressants inhibited the decline of CFSE levels
associated with NK cell proliferation, the inhibitory
effect of MPA was most prominent (Figure 1B). MPA
blocked the CFSE decline almost completely, even in
cells harvested after 9 days of culture. The inhibitory
effect of MPA on NK cell proliferation was dose-
dependent, as shown in Figure 1C. MPA inhibited
NK cell proliferation at a much lower concentration
(1 mg/mL) than that achieved after the administration
of standard-dose MMF. These results indicate that
MPA inhibits NK cell proliferation more potently
than the other immunosuppressants at a concentrationed by IL-2 and IL-15. (A) NK cells isolated from healthy individuals were
control (EtOH 0.1%, MPA 10 mg/mL, CSP 1000 ng/mL, TAC 20 ng/mL, or
ean6 SD; n5 6) of NK cells calculated by dividing the number of cells
cantly less degree of proliferation (P\.05) than the vehicle controls. (B)
at days 1, 5, and 9 of culture. The figure shows a representative set of
wed similar results. (C) NK cells were cultured in the presence of IL-2
tical axis represents the fold expansion (mean 6 SD; n 5 4) of NK cells
n asterisk indicates values showing significantly less proliferation (P\.05)
Figure 2. Changes in the NK cell phenotype after a 1-week culture
with different immunosuppressants. NK cells were cultured in the pres-
ence of IL-2 (100 U/mL) and IL-15 (10 ng/mL) with different immunosup-
pressants or a vehicle for 7 days, and the percentages of CD56dimCD161
and CD56higCD16- cells before and after culture were determined. (A)
Scattergrams of a representative donor from 4 different ones. The anal-
yses of other individuals produced similar results. (B) The percentages of
CD56highCD16- NK cells in the total CD3-CD561 cells after culture in
the presence of various immunosuppressants. The y-axis represents the
mean percentage 6 SD of CD56highCD16- NK cells calculated from 4
different experiments. An asterisk indicates a value showing a significant
difference in the CD56highCD16- NK cell percentage compared with the
vehicle control.
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of standard doses.
Changes in NK Cell Phenotype Associated with
Immunosuppressants
NK cells can be separated into 2 subsets on the ba-
sis of CD56 density and CD16 expression [16], namely
CD56dimCD161 cells, characterized by potent cyto-
toxicity, and CD56bright CD16- cells, featuring high
cytokine secretion activity. The 1-week culture of
NK cells with EtOH alone resulted in an increase in
CD56brightCD16- cells, with a reciprocal decrease in
CD56dimCD161 cells. The addition ofMPAmarkedly
reduced the proportion of CD56brightCD16- cells and
left CD56dimCD161 cells unchanged. CSP and TAC
reduced the proportion of CD56dimCD161 cells and
reciprocally increased that of CD56brightCD16- cells,
whereas MTX did not affect the proportion of either
subset (Figure 2A). Figure 2B shows the proportion
of the CD56brightCD16- NK cell subpopulation after
7 days of culture with immunosuppressants or EtOH
alone. The median proportion of this NK cell subset
was significantly lower in the culture with MPA
(4.0%) than in the vehicle control (15.5%). In contrast,
the proportion was significantly higher in the culture
with CSP (36.5%) and TAC (33.0%) than in the con-
trol, whereas the proportion of the culture with MTX
(17.5%) was comparable to that in the control.
Effect of Immunosuppressants on NK Cell
Receptor Expression
Activating NK cell receptor expression after a
1-week culture was compared among the NK cells
treated with the different immunosuppressants using
the relative geometric mean fluorescent intensity
(MFI) of NKG2D, NKp30, NKp44, and NKp46 to
that of the control culture. NKG2D expression was
decreased significantly after the treatment with TAC
and MPA. In contrast, NKp30 expression was aug-
mented significantly by CSP and TAC (Figure 3;
P\.05). Of note, the expression of all NK-activating
receptors decreased significantly after MPA treatment
(Figure 3; P\.05), suggesting poor cytotoxic function
of MPA-treated NK cells.
Cytotoxicity of NK Cells Treated with
Immunosuppressants
Figure 4A shows specific cytotoxicities against
K562 and Daudi cells at an effector:target ratio of
1:1. MPA-treated NK cells showed significantly lower
cytotoxicity against K562 cells (61.3% 6 14.5% vs
16.7% 6 6.7%; P \.01) and Daudi cells (44.0% 6
3.6% vs 4.3% 6 4.0%; P \.01) compared with the
control. There was a trend toward a higher cytotoxic-
ity against Daudi cells in the CSP- or TAC-treated
NK cells, but this enhancing effect was not observedagainstK562 cells.MTXdid not affectNKcell cytotox-
icity against either cell line. The reduced cytotoxicity
against K562 and Daudi cells by NK cells treated with
MPA was dependent on the MPA dose (Figure 4B).
Effect of Guanosine on the Inhibition of NK Cell
Proliferation and Cytotoxicity by MPA
MPAhas been shown to inhibit T cell proliferation
by depleting pools of guanosine triphosphate (GTP) in
activated T cells through IMPDH inhibition, whereas
guanosine has been shown to be able to restore the
proliferation of MPA-treated T cells by increasing
the GTP concentration in T cells [17,18]. To
Figure 3. Changes in the expression of NK cell–activating receptors after culture with immunosuppressants. The changes in the expression levels of
NKp30, NKp44, NKp46, and NKG2D in NK cells from 5 different individuals after a 1-week culture with immunosuppressants are shown. The vertical
axis represents relative changes in the geometric MFI (gMFI) that is calculated by (gMFI of the receptor in each immunosuppressant -gMFI of the receptor
in control)/gMFI of the receptor in control) 100. An asterisk indicates a significant difference compared with the vehicle control. ‘‘–’’ denotes the mean
of the relative change.
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the NK cell inhibition by MPA, we examined the
effects of guanosine on NK cell proliferation and
cytotoxicity. As shown in Figure 5A, the addition of
guanosine to the culture partially restored the NK
cell proliferation that had been markedly inhibited
by MPA; NK cell expansion increased from 0.7 6
0.2-fold to 2.66 0.9-fold by guanosine. Guanosine sig-
nificantly increased the cytotoxicity against K562 by
MPA-treated NK cells (from 16.0% 6 7.0% to
36.7% 6 3.2%) (Figure 5B), indicating that IMPDH
inhibition is a major mechanism of NK cell inhibition
by MPA.MPA Inhibits Down-Regulation of CDK Inhibitor
p27
The down-regulation of the CDK inhibitor
p27Kip1 is a critical event in the control of G1- to S-
phase transition of T cells [19] and is dependent on
IL-2 signaling [20], possibly through the p21ras/Raf/
mitogen-activated or extracellular signal–regulated
protein kinase/extracellular signal–regulated kinasepathway [21]. MPA has been shown to inhibit down-
regulation of p27Kip1 and also to interfere with the
cytokine-dependent signals that control the cell cycle,
thereby inhibiting T cells from entering the mid-G1
phase of the cell cycle [10,22].
To determine whether a similar cell cycle inhibi-
tion is induced in NK cells by MPA, we examined ex-
pression of the p27Kip1 in culturedNK cells andT cells
in the presence or absence of MPA. As shown in
Figure 6, the degradation of p27Kip1 was induced in
both T and NK cells within 24 hours in the culture
with IL-2 (100 U/mL). Degradation of p27Kip1 did
not occur when the T and NK cells were stimulated
with IL-2 in the presence of 10 mg/mL of MPA.DISCUSSION
MMF is being increasingly used inGVHDprophy-
laxis after allo-HSCT because its use in combination
with calcineurin inhibitors (CIs) produces comparable
neutrophil recovery to that seen with the MTX 1 CI
regimen [23]. The MMF 1 CI regimen is commonly
Figure 4. Cytotoxicity of cultured NK cells against leukemia cell lines. (A) Cytotoxicities by NK cells against K562 and Daudi cells at a 1:1 E:Tratio after
the 1-week culture in the presence of different immunosuppressants were compared. The mean6 SD cytotoxicity from experiments using 3 different
donors is shown. An asterisk indicates a significant difference compared with the control. (B) Cytotoxicities by NK cells against K562 and Daudi cells at
a 1:1 E:Tratio after the 1-week culture in the presence of different concentration of MPAwere compared. Themean6 SD cytotoxicities of experiments
using NK cells from 3 different donors are shown.
210 Biol Blood Marrow Transplant 17:205-213, 2011K. Ohata et al.used as a GVHD prophylaxis regimen after cord blood
transplantation [24], with the anticipation of rapid he-
matologic recovery. Although the inhibitory effect of
MPA on T cells has been studied extensively, its effect
on NK cells remains unclear. The present study is the
first to document the potent inhibitory effects of
MPA on NK cells. MPA’s inhibiting effects on NK
cell proliferation and cytotoxic activity are apparently
more evident than those of other immunosuppressants,
including CSP, TAC, and MTX. The NK-activating
receptor expression of NK cells is down-regulated by
MPA, and the inhibitory effect is partially abrogated
by the addition of guanosine to the NK cell culture.
Wang et al. [8] recently reported that CSP inhibits
NK cell proliferation in a dose-dependent manner,
while increasing the proportion of CD56brightCD16-
NK cells as well as enhancing NK cell cytotoxicity
against K562 and the human Burkitt’s lymphoma cell
line Raji. The present study confirms that the culture
of NK cells in the presence of CSP results in enhanced
cytotoxicity of NK cells against Daudi cells, as well as
an increased proportion of CD56brightCD16- NKcells. Another CI, TAC, exhibited similar effects as
CSP on NK cells. In accordance with the previous re-
port, both CSP and TAC significantly augmented the
surface expression of NKp30. The NKp30 expression
level has been reported to correlate with the cytotoxi-
citic function of NK cells [25]. Thus, the augmented
NKp30 expression might account for the increased
cytotoxicity by CI-treated NK cells.
IMPDH is a rate-limiting enzyme in the de novo
synthesis of guanosine nucleotides.Mitogenic stimula-
tion of T cells results in a marked increase in IMPDH
activity and a 5-fold increase in the guanine nucleotide
pool [26,27]. MPA inhibits type II IMPDH, which is
expressed in activated lymphocytes more abundantly
than the type I IMPDH expressed by most leukocytes
[28]. The MPA-induced deprivation of guanosine nu-
cleotides from lymphocytes results in decreased glyco-
sylation and expression of some adhesion molecules,
thereby decreasing the recruitment of lymphocytes
and monocytes into sites of inflammation and graft
rejection [29]. The present study shows that the inhib-
itory effects of MPA on NK cells are also mediated in
Figure 5. Effect of guanosine on the MPA-induced NK cell inhibition.
NK cells were cultured in the presence of 10 mg/mL MPA with or with-
out 100 mM guanosin for 1 week, and the effects of guanosine on MPA-
induced NK cell growth inhibition (A) and cytotoxicity inhibition (B)
were assessed. The vertical axis in A and B represent the mean 6 SD
of the fold expansion calculated by dividing the cell number after culture
by that before culture and of the cytotoxicity by cultured NK cells
against K562 cells at a 1:1 E/Tratio determined from 4 different donors.
An asterisk indicates a significant difference (P\.05) compared with
vehicle controls.
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However, given MPA’s remarkable inhibitory effect
on NK cells, other mechanisms besides inhibition of
IMPDH might play a role in this NK cell inhibition.
Laliberte et al. [22] attributed MPA’s antiprolifera-
tive effect onT cells to the inhibition of cyclinD/cyclin-
dependent kinase 6 induction and down-regulation ofFigure 6. Effect of MPA on p27Kip1 expression by T cells and NK cells. T cells
the presence of IL-2 (100 U/mL) with or without MPA (10 mg/mL), and p27Kip
analysis with anti-p27Kip1–specific monoclonal antibody. The figure shows repthe CDK inhibitor p27Kip1 following phytohemagluti-
nin stimulation of peripheral blood lymphocytes.
p27Kip1 is a member of a family of CDK inhibitors
that includes p21Cip/Waf1 and p57Kip2 [20]. It binds to
both CDK2 and CDK6 and controls the activity of
cyclinD/CDK6and cyclinE/CDK2complexes. As a re-
sult, guanine nucleotide depletion byMPA significantly
retards the degradation of p27Kip1 after T cell activa-
tion, and p27Kip1 gene expression by T cells, which de-
creases over time after incubation with IL-2, is blocked
by MPA [30]. Our findings indicate that MPA also
inhibits the IL-2–induced down-regulation of p27Kip1
in NK cells, although the expression level of p27Kip1
in NK cells was much lower than that in T cells. It is
plausible that the diminished degradation of p27Kip1 in-
duced byMPA during NK cell activation leads to an in-
crease in the amount of p27Kip1 available for inhibiting
cyclin E/CDK2 activity. Rapamycin, another potent
immunosuppressant, is known to prevent the activation
of cyclin E/CDK2 kinase activity and the degradation
of p27Kip1 associated with T cell activation [31]. Chen
et al. [32] recently demonstrated the potent inhibitory
effect of rapamycin (sirolimus) on NK cells. Thus, the
inhibition of the p27Kip1 degradation might be a com-
mon mechanism underlying NK cell inhibition by
immunosuppressive agents.
NK cells play an important role in the develop-
ment of the GVL effect after allo-HSCT, particularly
in transplants from HLA-haploidentical donors who
have KIR-L mismatches in the GVHD direction.
Recently, Dunbar et al. [33] reported an association
between highNK cell reconstitution and reduced rates
of relapse and death, with no increase in the incidence
of GVHD after reduced-intensity conditioning allo-
HSCT. Thus, the use of a GVHD prophylaxis regimen
that does not impair the reconstitution and function of
NK cells early after HSCT is critical. Willemze et al.
[34] recently reported a significantly lower relapse
rate of AML after cord blood transplantation (CBT)
from KIR-L–mismatched donors than after CBTand NK cells were harvested at the indicated time points after culture in
1 protein in the T cell and NK cell lysate was detected by Western blot
resentative results from 5 experiments.
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another study failed to demonstrate the beneficial
effect of KIR-L mismatches in CBT recipients [35].
Only 16% of the 218 patients analyzed in the former
study received a GVHD prophylaxis regimen that in-
cluded MMF [34], whereas 78% of the 257 patients
treated in the latter study received MMF [34]. Al-
though a number of factors are involved in the differ-
ent outcomes between these 2 studies, the use of
MMF and the resultant NK cell impairment might
be one reason for the difference in the KIR-L–mis-
match effect between the 2 studies. Thus, the possible
negative effect of MMF on the GVL effect after SCT
from KIR-L–mismatched donors merits examination
in a prospective randomized study.
In conclusion, our in vitro study shows that MPA
has a more potent inhibitory effect on NK cells than
other immunosuppresants commonly used for
GVHD prophylaxis. Thus, the combination of MTX
1 CI might be preferred over MMF 1 CI in terms
of the retention of the NK cell–mediated GVL effect
as a GVHD prophylaxis regimen.ACKNOWLEDGMENTS
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